Researchers tested a new experimental drug called MI-891 that blocks a protein in the liver called PXR. This protein normally tells the liver to make and store more fat. In studies with specially designed mice eating a high-fat diet, the drug successfully reduced the amount of fat stored in the liver and changed how that fat was structured. The mice treated with MI-891 showed lower levels of genes that create fat and store it in liver cells. This is the first study showing that blocking PXR could be a new way to treat fatty liver disease, a growing health problem affecting millions of people worldwide.
The Quick Take
- What they studied: Whether a new drug that blocks a liver protein called PXR could reduce fat buildup in the liver
- Who participated: Female laboratory mice that were genetically modified to have human liver proteins and were fed a high-fat diet to develop fatty liver disease
- Key finding: Mice treated with MI-891 had significantly lower levels of triglycerides (a type of fat) in their livers, and the genes responsible for making and storing fat were turned down
- What it means for you: This early-stage research suggests a potential new treatment approach for fatty liver disease, but it’s still in animal testing and much more research is needed before it could be used in humans
The Research Details
Scientists used specially bred laboratory mice that had human versions of liver proteins inserted into their genes. These mice were fed a high-fat diet to develop fatty liver disease, similar to what happens in some people. The researchers then gave some mice the experimental drug MI-891, which blocks a protein called PXR that normally tells the liver to make more fat. They compared the livers of treated mice to untreated mice to see what changed.
The researchers used advanced testing methods to measure the exact types and amounts of fat in the liver (called lipidomic analysis) and checked which genes were turned on or off using molecular testing techniques. This allowed them to see not just whether fat decreased, but also how the liver’s fat-making machinery changed in response to the drug.
This type of study is important because it allows researchers to test new drugs in a controlled way before considering human trials, and the humanized mice more closely mimic how the drug might work in actual people.
Understanding how to block PXR is important because this protein is a major driver of fat accumulation in the liver. By studying this in mice with human liver proteins, researchers can predict more accurately how the drug might work in people. The detailed fat analysis shows exactly how the drug changes liver metabolism, not just whether it reduces fat overall.
This is a preliminary laboratory study using animal models, which is an appropriate first step in drug development. The use of humanized mice (mice with human liver proteins) makes the findings more relevant to humans than regular mice would be. However, animal studies don’t always translate to human results, so much more testing would be needed. The study appears to be well-designed with appropriate control groups and multiple testing methods to confirm findings.
What the Results Show
The main finding was that MI-891 treatment significantly reduced triglyceride levels in the livers of mice eating a high-fat diet. The drug didn’t just reduce the total amount of fat—it also changed the types of fat present, shifting toward less saturated fats, which may be healthier.
When researchers examined which genes were active in the liver, they found that MI-891 turned down multiple genes responsible for making new fat (including genes called Scd1, Thrsp, and Acaca) and genes involved in storing fat in droplets within liver cells (Plin2 and Hsd17b13). This suggests the drug works by reducing the liver’s ability to manufacture and store fat.
The researchers confirmed that the drug was actually blocking PXR by showing that CYP3A4, a gene directly controlled by PXR, was turned down at both the genetic level and the protein level. This proves the drug was doing what it was designed to do—inhibiting PXR activity in the liver.
Beyond the main findings, the study showed that blocking PXR affects multiple pathways involved in fat metabolism. The shift in the saturation profile of triglycerides (toward less saturated fats) is particularly interesting because saturated fats are generally considered less healthy. The reduction in lipid droplet-associated genes suggests the liver cells were not just making less fat, but also losing their ability to store what fat was present.
Previous research has shown that activating PXR (turning it on) causes the liver to make more fat and accumulate it, contributing to fatty liver disease. This is the first study to comprehensively examine what happens when you do the opposite—block or inhibit PXR. The findings support the theory that PXR is a key driver of fatty liver disease and suggest that blocking it could be therapeutic. This represents a new direction in fatty liver disease treatment research.
This study was conducted only in laboratory mice, not in humans, so we don’t know yet if the drug will work the same way in people. The mice were genetically modified to have human liver proteins, which helps but isn’t identical to human biology. The study doesn’t tell us about potential side effects or whether the drug is safe for long-term use. Additionally, the sample size of mice isn’t specified in the available information, and we don’t know how long the effects lasted or whether they would persist over time.
The Bottom Line
At this stage, MI-891 cannot be recommended for human use as it is still in early research phases. The findings suggest that PXR inhibition is a promising direction for treating fatty liver disease, but multiple additional studies in animals and eventually humans would be needed before clinical use. Current evidence level: Preliminary animal research (very early stage).
People with fatty liver disease or those at risk for it should be aware of this research direction, as it may lead to new treatment options in the future. Healthcare providers treating fatty liver disease should follow this research area. However, no one should seek out this drug or similar compounds yet, as they are not approved for human use. People interested in liver health can use this as motivation to maintain healthy weight and diet while waiting for new treatments to be developed.
This is very early-stage research. If the drug continues to show promise, it would typically take 5-10+ years of additional testing before it could potentially be available to patients. Animal studies must be followed by laboratory safety testing, then human clinical trials in multiple phases. Realistic expectations: This is a promising lead, but practical applications are years away.
Want to Apply This Research?
- Users interested in fatty liver disease management could track weekly measurements of waist circumference and weight, along with dietary fat intake (grams per day), to monitor their own liver health while following current evidence-based recommendations
- Users could set a goal to reduce saturated fat intake and increase physical activity to 150 minutes per week, logging meals and exercise sessions to track progress toward liver-healthy habits
- Establish a long-term tracking system for weight, exercise consistency, and dietary choices. Users should work with their healthcare provider to monitor liver function through periodic blood tests (ALT, AST levels) and potentially ultrasound imaging to assess fatty liver status over time
This article describes early-stage laboratory research in mice and does not represent approved medical treatment. MI-891 is an experimental compound not available for human use. If you have fatty liver disease or concerns about liver health, consult with your healthcare provider about evidence-based treatment options currently available. Do not attempt to obtain or use experimental drugs without medical supervision. This research is promising but preliminary, and many years of additional testing would be required before any potential human application.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.